FLT3 and acute myeloid leukemia: Compared with the 2Iglow group, 2Ighigh AML patients had the older age (P = 0.026), lower NPM1 mutation (P = 0.012), higher FLT3-ITD mutation (P = 0.047), the declining complete remission (CR) rates after standard induction therapy for 2 cycles (P = 0.028), and a worse trend of karyotype classification (P = 0.056).